XM은(는) 미국 국적의 시민에게 서비스를 제공하지 않습니다.

XM은(는) 미국 국적의 시민에게 서비스를 제공하지 않습니다.
B
B

BectonDickinson

뉴스

Reuters - 2 일 전

BD, Quest Diagnostics Join Forces to Develop Companion Diagnostics for Cancer, Other Diseases

BRIEF-BD, Quest Diagnostics Join Forces to Develop Companion Diagnostics for Cancer, Other Diseases July 25 (Reuters) - Becton Dickinson and Co BDX.N : BD: CO, QUEST DIAGNOSTICS TO DEVELOP, MANUFACTURE AND COMMERCIALIZE FLOW CYTOMETRY-BASED COMPANION DIAGNOSTICS BD: OFFERINGS WILL INCLUDE EXPLORATORY PANEL DEVELOPMENT, MANUFACTURING & DISTRIBUTION
B
Reuters - 2 일 전

Edwards Lifesciences falls after missing Q2 revenue estimates

BUZZ-Edwards Lifesciences falls after missing Q2 revenue estimates ** Shares of medical device maker Edwards Lifesciences EW.N fall more than 16% to $72.7 in after-hours trading ** Co misses Q2 revenue estimates, hurt by lower-than-expected demand for its artificial heart valves ** Posts revenue of $1.39 bln, missing analysts' estimates of $1.65 bl
B
Reuters - 2 일 전

Edwards Lifesciences misses Q2 revenue estimates on weak demand for heart devices

REFILE-Edwards Lifesciences misses Q2 revenue estimates on weak demand for heart devices Corrects day in first paragraph July 24 (Reuters) - Edwards Lifesciences EW.N missed second-quarter revenue estimates on W ednesday , hurt by lower-than-expected demand for its artificial heart valves. Shares of the California-based company were down 14.3% at $74.50 after the bell.
A
B
Reuters - 3 일 전

BD Board Declares Dividend

BRIEF-BD Board Declares Dividend July 23 (Reuters) - Becton Dickinson and Co BDX.N : BD - DECLARED A QUARTERLY DIVIDEND OF $0.95 PER COMMON SHARE Source text for Eikon: ID:nPn2W8Q9Ca Further company coverage: BDX.N
B
Reuters - 2 주 전

US FDA flags shortage of Becton Dickinson's blood test tubes

US FDA flags shortage of Becton Dickinson's blood test tubes July 10 (Reuters) - The U.S. Food and Drug Administration issued an alert on Wednesday to laboratories and healthcare providers of a shortage of Becton Dickinson' BDX.N blood test tubes used in diagnosing bacterial and fungal infections. The regulator urged providers to prioritize patients at the highest risk such as those displaying signs of bloodstream infections, which can often be deadly.
B
Reuters - 2 주 전

BD Says Supplier Issue With Bactec Blood Culture Vials Not Expected To Have Material Financial Impact

BRIEF-BD Says Supplier Issue With Bactec Blood Culture Vials Not Expected To Have Material Financial Impact July 10 (Reuters) - Becton Dickinson and Co BDX.N : BD STATEMENT ON SUPPLIER ISSUE IMPACTING BD BACTEC™ BLOOD CULTURE VIALS BD: EXPERIENCING REDUCED AVAILABILITY OF BLOOD CULTURE VIALS FROM OUR SUPPLIER BD - SUPPLIER ISSUE IS NOT EXPECTED T
B
Reuters - 2 주 전

FDA Says Aware That U.S. Is Experiencing Interruptions In The Supply Of Bd Bactec Blood Culture Media Bottles Because Of Recent Supplier Issues

BRIEF-FDA Says Aware That U.S. Is Experiencing Interruptions In The Supply Of Bd Bactec Blood Culture Media Bottles Because Of Recent Supplier Issues July 10 (Reuters) - FDA: AWARE THAT U.S. IS EXPERIENCING INTERRUPTIONS IN THE SUPPLY OF BD BACTEC BLOOD CULTURE MEDIA BOTTLES BECAUSE OF RECENT SUPPLIER ISSUES FDA: DISRUPTION IN SUPPLY OF BD BACTEC BLOOD CULTURE MEDIA BOTTLES IN U.S.
B
Reuters - 2 주 전

U.S. Nvidia, Qualcomm, Tesla

U.S. RESEARCH ROUNDUP-Nvidia, Qualcomm, Tesla July 10 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Nvidia, Qualcomm and Tesla, on Wednesday. HIGHLIGHTS * Brighthouse Financial Inc BHF.O : Jefferies raises to buy from hold * Legalzoom.Com Inc LZ.O : JP Morgan cuts to neutral from overweight * Nvidia Corp NVDA.O : KeyBanc raises target price to $180 * Qualcomm Inc QCOM.O : KeyBanc raises target price to $225 * Tesla
A
A
A
A
A
C
G
M
M
N
P
Q
S
T
A
A
A
C
O
B
T
A
A
A
A
C
G
L
U
Reuters - 1 달 전

U.S. Adobe, Oracle, Zscaler

U.S. RESEARCH ROUNDUP-Adobe, Oracle, Zscaler June 14 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Adobe, Oracle Corp and Zscaler, on Friday. HIGHLIGHTS * Adobe Inc ADBE.O : Baird raises target price to $545 from $525 * Bandwidth Inc BAND.O : Morgan Stanley cuts to underweight from equal-weight * Corpay Inc CPAY.N : Jefferies cuts target price to $295 from $330 * Oracle Corp ORCL.N : Berenberg raises target price t
A
A
A
B
H
H
M
B
C
D
Reuters - 2 달 전

Becton, Dickinson And Co Files For Offering Of $600 Million 5.081% Notes Due 2029 - SEC Filing

BRIEF-Becton, Dickinson And Co Files For Offering Of $600 Million 5.081% Notes Due 2029 - SEC Filing June 4 (Reuters) - Becton Dickinson and Co BDX.N : BECTON, DICKINSON AND CO FILES FOR OFFERING OF $600 MILLION 5.081% NOTES DUE 2029 - SEC FILING Source text for Eikon: [ID:n0001140361-24-028860] Further company coverage: BDX.N
B
Reuters - 2 달 전

Becton Dickinson Euro Finance S.À R.L Files For Offering Of €800 Million 4.029% Notes Due 2036 - SEC Filing

BRIEF-Becton Dickinson Euro Finance S.À R.L Files For Offering Of €800 Million 4.029% Notes Due 2036 - SEC Filing June 4 (Reuters) - Becton Dickinson and Co BDX.N : BECTON DICKINSON EURO FINANCE S.À R.L FILES FOR OFFERING OF €800 MILLION 4.029% NOTES DUE 2036 - SEC FILING Source text for Eikon: [ID:n0001140361-24-028859] Further company cover
B
Reuters - 2 달 전

Becton, Dickinson And Company Files For Offering Of €1 Billion 3.828% Notes Due 2032 -SEC Filing

BRIEF-Becton, Dickinson And Company Files For Offering Of €1 Billion 3.828% Notes Due 2032 -SEC Filing June 4 (Reuters) - Becton Dickinson and Co BDX.N : BECTON, DICKINSON AND COMPANY FILES FOR OFFERING OF €1 BILLION 3.828% NOTES DUE 2032 -SEC FILING Source text for Eikon: [ID:n0001140361-24-028858] Further company coverage: BDX.N
B
Reuters - 2 달 전

Deals of the day-Mergers and acquisitions

Deals of the day-Mergers and acquisitions Adds Paramount Global, Deutsche Telekom June 3 (Reuters) - The following bids, mergers, acquisitions and disposals were reported by 2000 GMT on Monday: ** Skydance Media was awaiting a response to its enhanced bid for entertainment conglomerate Paramount Global PARA.O , in which it offered to buy nearly half of the nonvoting Paramount shares at $15 each, according to a source familiar with the matter.
D
R
B
Reuters - 2 달 전

U.S. STOCKS Arrowhead, Novavax, Precigen

BUZZ-U.S. STOCKS ON THE MOVE-Arrowhead, Novavax, Precigen Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: https://refini.tv/3LI4BU7 The Morning News Call newsletter: https://refini.tv/3dKUyB8 The Nasdaq and the S&P 500 inched up on Monday as falling U.S. Treasury yields boosted megacap growth stocks, while investors assessed data that showed local manufacturing activity had eased for the second consecutive month in May.
A
B
C
G
J
J
U
U
B
S
P
Reuters - 2 달 전

Deals of the day-Mergers and acquisitions

Deals of the day-Mergers and acquisitions Adds: Stericycle, Edwards Lifesciences, Pershing Square Capital Management, LexisNexis, STC Group Updates: Waste Management June 3 (Reuters) - The following bids, mergers, acquisitions and disposals were reported by 1330 GMT on Monday: ** Waste Management said it will take Stericycle SRCL.O private in a deal valued at $7.2 billion, as it looks to tap into the growing healthcare waste disposal market in the United States.
R
B
Reuters - 2 달 전

Edwards Lifesciences rises; to sell critical care unit for $4.2 bln

BUZZ-Edwards Lifesciences rises; to sell critical care unit for $4.2 bln ** Shares of medical device maker Edwards Lifesciences EW.N rise 3.4% to $89.80 premarket ** Says it has agreed to sell its critical care products unit to Becton Dickinson BDX.N in an all-cash transaction valued at $4.2 billion ** With this agreement, co is no longer pursuing
B
Reuters - 2 달 전

Edwards to sell critical care products unit to Becton Dickinson for $4.2 bln

UPDATE 3-Edwards to sell critical care products unit to Becton Dickinson for $4.2 bln Adds analyst comment in paragraph 3 and background paragraph 4 onwards By Pratik Jain June 3 (Reuters) - Edwards Lifesciences EW.N on Monday said it has agreed to sell its critical care products unit to Becton Dickinson BDX.N in an all-cash deal valued at $4.2 billion to sharpen focus on its heart devices business.
B
Reuters - 2 달 전

Edwards Lifesciences To Sell Critical Care To BD

BRIEF-Edwards Lifesciences To Sell Critical Care To BD June 3 (Reuters) - Edwards Lifesciences Corp EW.N : EDWARDS LIFESCIENCES TO SELL CRITICAL CARE TO BD EDWARDS LIFESCIENCES SELLS CRITICAL CARE TO BD FOR $4.2 BILLION EDWARDS LIFESCIENCES CORP - PROPOSED DEAL FOR $4.2 BILLION EDWARDS TO FUND STRATEGIC GROWTH INVESTMENTS FROM SALE PROCEEDS EDWARDS
B
Reuters - 2 달 전

Edwards Lifesciences to sell its critical products unit to Becton Dickinson for $4.2 bln

Edwards Lifesciences to sell its critical products unit to Becton Dickinson for $4.2 bln June 3 (Reuters) - Edwards Lifesciences EW.N on Monday said it has agreed to sell its critical care products unit to Becton, Dickinson and Co BDX.N in an all-cash transaction valued at $4.2 billion. Reporting by Pratik Jain in Bengaluru; Editing by Tasim Zahid
B
Reuters - 2 달 전

BD To Acquire Edwards Lifesciences' Critical Care Product Group For $4.2 Bln

BRIEF-BD To Acquire Edwards Lifesciences' Critical Care Product Group For $4.2 Bln June 3 (Reuters) - BD and Edwards Lifesciences: BD TO ACQUIRE EDWARDS LIFESCIENCES' CRITICAL CARE PRODUCT GROUP FOR $4.2 BILLION TO EXPAND SMART CONNECTED CARE SOLUTIONS AND BECOME AN ADVANCED MONITORING TECHNOLOGY LEADER BD: EXPECTS TO FUND ALL-CASH TRANSACTION WITH
B

조건

인기 자산

면책조항: XM Group 회사는 체결 전용 서비스와 온라인 거래 플랫폼에 대한 접근을 제공하여, 개인이 웹사이트에서 또는 웹사이트를 통해 이용 가능한 콘텐츠를 보거나 사용할 수 있도록 허용합니다. 이에 대해 변경하거나 확장할 의도는 없습니다. 이러한 접근 및 사용에는 다음 사항이 항상 적용됩니다: (i) 이용 약관, (ii) 위험 경고, (iii) 완전 면책조항. 따라서, 이러한 콘텐츠는 일반적인 정보에 불과합니다. 특히, 온라인 거래 플랫폼의 콘텐츠는 금융 시장에서의 거래에 대한 권유나 제안이 아닙니다. 금융 시장에서의 거래는 자본에 상당한 위험을 수반합니다.

온라인 거래 플랫폼에 공개된 모든 자료는 교육/정보 목적으로만 제공되며, 금융, 투자세 또는 거래 조언 및 권고, 거래 가격 기록, 금융 상품 또는 원치 않는 금융 프로모션의 거래 제안 또는 권유를 포함하지 않으며, 포함해서도 안됩니다.

이 웹사이트에 포함된 모든 의견, 뉴스, 리서치, 분석, 가격, 기타 정보 또는 제3자 사이트에 대한 링크와 같이 XM이 준비하는 콘텐츠 뿐만 아니라, 제3자 콘텐츠는 일반 시장 논평으로서 "현재" 기준으로 제공되며, 투자 조언으로 여겨지지 않습니다. 모든 콘텐츠가 투자 리서치로 해석되는 경우, 투자 리서치의 독립성을 촉진하기 위해 고안된 법적 요건에 따라 콘텐츠가 의도되지 않았으며, 준비되지 않았다는 점을 인지하고 동의해야 합니다. 따라서, 관련 법률 및 규정에 따른 마케팅 커뮤니케이션이라고 간주됩니다. 여기에서 접근할 수 있는 앞서 언급한 정보에 대한 비독립 투자 리서치 및 위험 경고 알림을 읽고, 이해하시기 바랍니다.

리스크 경고: 고객님의 자본이 위험에 노출 될 수 있습니다. 레버리지 상품은 모든 분들에게 적합하지 않을수 있습니다. 당사의 리스크 공시를 참고하시기 바랍니다.